PRAXIS PRECISION MEDICINES I

Praxis Precision’s CEO sells shares amid a booming 31.5% monthly gain and a new Remagine Labs partnership, signaling routine portfolio moves, not a confidence dip.

Jill DeSimone’s latest insider trades show disciplined buying and selling, signaling long‑term confidence in Praxis Precision Medicines’ soaring biotech prospects.